Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KYSA-7 study of KYV-101 in refractory progressive multiple sclerosis
2024-511168-10-00Phase 2Authorised
- Sponsor
- Kyverna Therapeutics
- Start
- Oct 2024
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 5
01
Overview
Phase 2, randomised, open-label trial of mivocabtagene autoleucel in primary progressive multiple sclerosis (PPMS) and secondary-progressive multiple sclerosis (SPMS) (2 arms), sponsored by Kyverna Therapeutics. Primary endpoint: Confirmed disability progression. Planned start Oct 2024; status: authorised.
02
Drugs
mivocabtagene autoleucel
03
Conditions
primary progressive multiple sclerosis (PPMS)secondary-progressive multiple sclerosis (SPMS)
Beyond the preview
Go deeper on 2024-511168-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511168-10-00.